Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Rekah Pharmaceutical ProdXTAE:REKA 57 OCF Yield % is 8.36 as of Jul. 14, 2026, which is 19% below its 10-year median of 10.38. GuruFocus rates XTAE:REKA with a GF Score™ of 57/100 and a GF Value™ of ₪13.05 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 1,007 Drug Manufacturers companies, Rekah Pharmaceutical Prod ranks better than 74.58% on this metric.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Rekah Pharmaceutical Prod OCF Yield % Related Terms
Rekah Pharmaceutical Prod OCF Yield % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XTAE:REKA vs ZTS, UTHR, VTRS: OCF Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Rekah Pharmaceutical Prod's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rekah Pharmaceutical Prod OCF Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Rekah Pharmaceutical Prod's OCF Yield % distribution charts can be found below:
* The bar in red indicates where Rekah Pharmaceutical Prod's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rekah Pharmaceutical Prod (XTAE:REKA) has a OCF Yield % of 8.36 as of Jul. 14, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Rekah Pharmaceutical Prod and its competitors. This is 19% below median its historical median of 10.38. Over the past decade, Rekah Pharmaceutical Prod's OCF Yield % has ranged from 0.70 to 28.12. According to the industry distribution chart, Rekah Pharmaceutical Prod ranks #256 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 25.4%.
Is Rekah Pharmaceutical Prod's OCF Yield % too high?
Rekah Pharmaceutical Prod's current OCF Yield % of 8.36 is 19% below median its 10-year median of 10.38. Over the past 10 years, this metric has ranged from a low of 0.70 to a high of 28.12. The Drug Manufacturers industry median OCF Yield % is 3.53. Rekah Pharmaceutical Prod's value of 8.36 is 136.8% above this industry median. Based on the distribution chart, Rekah Pharmaceutical Prod ranks #256 out of 1007 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Rekah Pharmaceutical Prod has a GF Score™ of 57/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Rekah Pharmaceutical Prod's OCF Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Rekah Pharmaceutical Prod ranks #256 out of 1007 companies for OCF Yield %. This puts Rekah Pharmaceutical Prod in the upper half of its industry. The industry median OCF Yield % is 3.53. Rekah Pharmaceutical Prod's value of 8.36 is 136.8% above this benchmark. Historically, Rekah Pharmaceutical Prod's own OCF Yield % has ranged from 0.70 to 28.12 over the past decade. While the company's 10-year median is 10.38 vs. the industry median of 3.53, Rekah Pharmaceutical Prod has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Drug Manufacturers company?
The median OCF Yield % among Drug Manufacturers companies is 3.53, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a OCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rekah Pharmaceutical Prod's current OCF Yield % of 8.36 is 136.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Rekah Pharmaceutical Prod and its competitors. For the Drug Manufacturers industry, the median OCF Yield % is 3.53 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rekah Pharmaceutical Prod's current OCF Yield % is 8.36, which is 19% below median its own 10-year median of 10.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rekah Pharmaceutical Prod stock overvalued right now?
Based on GuruFocus' analysis, Rekah Pharmaceutical Prod (XTAE:REKA) is currently considered Modestly Undervalued. The stock's GF Value™ is ₪13.05, compared to a current price of ₪10.30 — trading 21.1% below its estimated fair value. The current OCF Yield % is 8.36, which is 19% below median its 10-year median of 10.38 and 136.8% above the Drug Manufacturers industry median of 3.53. Rekah Pharmaceutical Prod's overall GF Score™ is 57/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Rekah Pharmaceutical Prod (XTAE:REKA), the current OCF Yield % is 8.36 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Rekah Pharmaceutical Prod (XTAE:REKA) Overvalued in 2026?
Based on GuruFocus' analysis, Rekah Pharmaceutical Prod stock appears to be undervalued.
The current stock price of ₪10.30 is trading 21.1% below its estimated GF Value™ of ₪13.05.
GuruFocus considers Rekah Pharmaceutical Prod to be Modestly Undervalued.
Key valuation signals for XTAE:REKA:
OCF Yield %: 8.36 (19% below median its 10-year median of 10.38)
GF Value™: ₪13.05 vs. price of ₪10.30 (21.1% below fair value)
Industry Position: 136.8% above the Drug Manufacturers median (#256 of 1007)
No single metric tells the full story. See the XTAE:REKA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Rekah Pharmaceutical Prod Ltd is engaged in the manufacturing, importing, marketing, and distribution of pharmaceuticals and cosmetics. It primarily caters to the needs of hospitals, retirement homes, and national medical healthcare services.
57GF Score
Get the complete analysis for XTAE:REKA
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTAE:REKA has been successfully added to your 
